|
Post by Niels on Nov 8, 2006 14:09:44 GMT -5
I guess this is where all my idiot-insurance-co docs get their misinformation allowing them to claim "you can't have lyme disease because you've been on antibiotics longer than a month" (despite two different Igenex IGG/IGM tests and an LLMD saying otherwise...) www.nlm.nih.gov/medlineplus/print/news/fullstory_40347.html.................. Long-Term Antibiotics Won't Fight Lyme Disease Therapy beyond one month may even be hazardous, experts say URL of this page: www.nlm.nih.gov/medlineplus/news/fullstory_40347.html (*this news item will not be available after 01/20/2007) Healthday HealthDay Robert Preidt Sunday, October 22, 2006 SUNDAY, Oct. 22 (HealthDay News) -- Long-term antibiotic treatment of people with Lyme disease has not proven to be effective, and use of the drugs for more than four weeks may even be dangerous, according to new expert guidelines. The updated Lyme disease diagnosis and treatment guidelines were released by the Infectious Diseases Society of America (IDSA). The guidelines also note that 95 percent of cases of Lyme disease are cured within 10 to 28 days of treatment with oral antibiotics. Major changes in the guidelines, originally published in 2002, include: * The addition of information on human granulocytic anaplasmosis (HGA) and babesiosis, two diseases transmitted by the same tick that transmits Lyme disease. * Recommendations of a single dose of the antibiotic doxycycline for certain high-risk people who've been bitten by a tick by don't have symptoms of Lyme disease. * More information about so-called "chronic" or post-Lyme syndromes. This refers to patients who report a variety of non-specific symptoms -- such as generalized pain, joint pain, or fatigue -- after they've been appropriately treated with antibiotics. The updated guidelines are expected to be available shortly on the IDSA Web site at www.idsociety.org and to be published in the Nov. 1 issue of the journal Clinical Infectious Diseases. "We worked to make the guidelines as comprehensive as possible based on a thorough review of all credible scientific literature," lead author Dr. Gary P. Wormser, chief of the division of infectious diseases and vice chairman of the department of medicine at New York Medical College, said in a prepared statement. Wormser was chair of the expert panel that developed the updated guidelines. Lyme disease is transmitted by the black-legged deer tick. The disease has been reported across the United States, but the majority of cases occur in the mid-Atlantic and Northeast states. ............
|
|
|
Post by Niels on Nov 8, 2006 14:15:45 GMT -5
www.journals.uchicago.edu/CID/journal/issues/v43n9/40897/40897.web.pdfClinical Infectious Diseases 2006;43:1089-1134 © 2006 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2006/4309-0001$15.00 IDSA GUIDELINES The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America Gary P. Wormser,1 Raymond J. Dattwyler,2 Eugene D. Shapiro,5,6 John J. Halperin,3,4 Allen C. Steere,9 Mark S. Klempner,10 Peter J. Krause,8 Johan S. Bakken,11 Franc Strle,13 Gerold Stanek,14 Linda Bockenstedt,7 Durland Fish,6 J. Stephen Dumler,12 and Robert B. Nadelman1 Divisions of 1Infectious Diseases and 2Allergy, Immunology, and Rheumatology, Department of Medicine, New York Medical College, Valhalla, and 3New York University School of Medicine, New York, New York; 4Atlantic Neuroscience Institute, Summit, New Jersey; Departments of 5Pediatrics and 6Epidemiology and Public Health and 7Section of Rheumatology, Department of Medicine, Yale University School of Medicine, New Haven, and 8Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children's Medical Center, Hartford; 9Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, and 10Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts; 11Section of Infectious Diseases, St. Luke's Hospital, Duluth, Minnesota; 12Division of Medical Microbiology, Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland; 13Department of Infectious Diseases, University Medical Center, Ljubljana, Slovenia; and 14Medical University of Vienna, Vienna, Austria Evidence-based guidelines for the management of patients with Lyme disease, human granulocytic anaplasmosis (formerly known as human granulocytic ehrlichiosis), and babesiosis were prepared by an expert panel of the Infectious Diseases Society of America. These updated guidelines replace the previous treatment guidelines published in 2000 (Clin Infect Dis 2000; 31[Suppl 1]:1–14). The guidelines are intended for use by health care providers who care for patients who either have these infections or may be at risk for them. For each of these Ixodes tickborne infections, information is provided about prevention, epidemiology, clinical manifestations, diagnosis, and treatment. Tables list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease and provide a partial list of therapies to be avoided. A definition of post–Lyme disease syndrome is proposed.
|
|
|
Post by belikewater on Nov 8, 2006 14:38:13 GMT -5
I believe, based on information in the Lyme and Rife book, that Lyme quickly becomes resistant to a specific antibiotic. You must use a program of pulsed chemicals, preferably a combination of herbals and pharmaceuticals and protein interferers and anti-parasiticals.
If you use the cephalosporins or penicillins that interfere with the cell wall, the Bb bug will just lose its cell wall, become an L-form and start you on the road to sarciodoisis.
|
|
|
Post by Niels on Nov 9, 2006 1:18:51 GMT -5
at least there's now some common acceptance that "Acrodermatitis chronica atrophicans" (normally assoc'd w/ european lyme) is part of the Lyme diagnosis in the USA. In other words, finally, something other than the "bullseye rash" in dermatology to account for a dermatological manifestation of Lyme disease. Also intersting language used... successful treatment results in "diminution in fibrous nodules."
For some of us with lyme diagnosis and appropriate bands lit-up on the igenex lyme igg/igm test, that may be the evidence we need to document "disease" over "delusion" allowing us "lucky" lyme infected folks to receive proper medical care instead of psychotropic drugs. ................ Background and Diagnosis of Acrodermatitis Chronica Atrophicans
Acrodermatitis chronica atrophicans is a late skin manifestation of Lyme disease that develops insidiously several years after initial infection (range, 0.5–8 years) [109, 242].
Approximately 20% of patients have a history of a preceding erythema migrans lesion, usually of the same extremity [242]. Acrodermatitis chronica atrophicans is diagnosed most frequently in women >40 years of age. Although any of the species of Lyme Borrelia may cause the lesion, by far the most common etiologic agent is B. afzelii. Therefore, this manifestation is much more common in Europe than in the United States [243–246].
Acrodermatitis chronica atrophicans occurs most often on the extensor surfaces of the hands and feet, and early lesions are characterized by a slight bluish-red discoloration and doughy swelling. Initially unilateral, the lesion may later become bilateral. The lesion enlarges slowly over months to years, in association with resolution of the edema and development of skin atrophy (figure 4) (sometimes referred to as "cigarette paper skin"). Nodules may develop over bony prominences, such as the elbow or patella [197, 242, 247]. In some patients, sclerosing lesions develop. Because of atrophy of the skin, the veins become prominent, which may lead to a misdiagnosis of venous insufficiency [109, 197, 242]. Approximately two-thirds of patients have an associated peripheral neuropathy, typically involving the affected extremity, manifested primarily as local sensory loss [248, 249].
(95 kB)
Figure 4. Illustrative example of a patient with acrodermatitis chronica atrophicans. The picture is a generous gift from Dr. Franc Strle (University Medical Center, Ljubljana, Slovenia).
The diagnosis of acrodermatitis chronica atrophicans is based on appropriate epidemiology, clinical characteristics, histological findings, and IgG seropositivity. Histopathology shows a pronounced lymphoplasmacellular infiltration of the skin and sometimes also of the subcutis, with or without atrophy [195].
Evidence to support treatment recommendations. Acrodermatitis chronica atrophicans does not appear to resolve spontaneously. There are no prospective, randomized studies on treatment. Oral or parenteral antimicrobial therapy (table 2) given for 3 weeks (range, 2–4 weeks) has resulted in improvement in pain and swelling, diminution in fibrous nodules, and gradual fading of the lesion within 2–6 months [250–252]. Atrophic areas often persist, and little objective improvement can be demonstrated in the neuropathy in uncontrolled studies, regardless of whether antibiotics are administered parenterally. However, progression of neurologic involvement is halted, and the neuropathic symptoms of pain and paresthesia are improved [251, 252]. In the United States, treatment of Lyme disease–associated peripheral neuropathy with intravenous ceftriaxone usually results in improvement. The reasons for the differences in the experience with this manifestation of the disease in the United States and Europe are not clear.
Recommendations
1. Available data indicate that acrodermatitis chronica atrophicans may be treated with a 21-day course of the same antibiotics (doxycycline [B-II], amoxicillin [B-II], or cefuroxime axetil [B-III]) used to treat patients with erythema migrans (tables 2 and 3). A controlled study is warranted to compare oral with parenteral antibiotic therapy for the treatment of acrodermatitis chronica atrophicans. ................
|
|
|
Post by Niels on Nov 10, 2006 17:00:25 GMT -5
ACA seems to have a lot of morgellons-like characteristics, dontcha think? I guess perhaps since the big august medical bodies like the "Infectious Disease Society of America" write of various dermal manifestations of Lyme in the diagnosis and treatment guidelines... now perhaps morgellons sufferers can get treatment for their skin symptoms as lyme disease too?? Note that these european articles on cutaneous manifestations of Lyme are all over 10 years old... yet they cite morgellons-like characteristics in skin lesions and have now long been recognized and treated in europe as ACA-symptomps of Lyme disease. Maybe morgellons is just another variant of borrelia (the bacterial cause of Lyme), e.g. B. garinii, and B. afzelii ... www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=8338751&query_hl=6&itool=pubmed_docsum................ : Br J Dermatol. 1993 Jun;128(6):674-8. Links Cutaneous fibroses induced by Borrelia burgdorferi. * Marsch WC, * Mayet A, * Wolter M. Department of Dermatology, Johann Wolfgang Goethe-Universitat, Frankfurt am Main, Germany. Three cases of chronic infection with Borrelia burgdorferi are described. The patients presented with nodular or discoid fibrosis, partly in conjunction with acrodermatitis chronica atrophicans (ACA). Juxta-articular fibrotic nodules may develop within a few months of the onset of ACA. Nodular, discoid morphoea-like, and widespread cutaneous fibroses in chronic Borrelia infection may be provoked by trauma, surgery or electromagnetic radiation. They respond well to antibiotic therapy. These lesions offer an in vivo model for studying the evolution of immunologically induced fibrosis. PMID: 8338751 [PubMed - indexed for MEDLINE] ....................... www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=7955495&query_hl=6&itool=pubmed_docsum........................ Clin Exp Dermatol. 1994 Sep;19(5):394-8. Links Juxta-articular fibrotic nodules in Borrelia infection--ultrastructural details of therapy-induced regression. * Marsch WC, * Wolter M, * Mayet A. Department of Dermatology, Martin-Luther-Universitat, Halle (Saale)-Wittenberg, Germany. Juxta-articular fibrotic nodules in chronic Borrelia burgdorferi infection commonly regress rapidly under antibiotic therapy. They may therefore serve as a good in vivo model for studying the development and regression of cutaneous fibrotic processes. As shown in a typical case of acrodermatitis chronica atrophicans, this spirochete-induced fibrosis in the upper subcutis of the elbow region is histologically characterized by broad hyalinized collagen tracts interspersed with prominent perivascular lymphocytes and plasma cells. These immune cells vanish completely after 5 days of antibiotic treatment, while fibroblasts discharge matrix vesicles and form elastic fibres. PMID: 7955495 [PubMed - indexed for MEDLINE] ........................ www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=2759856............... Hautarzt. 1989 Jul;40(7):423-9. Links [Unusual manifestations of Lyme borreliosis. A contribution to the clinical spectrum of this disease group] [Article in German] * Detmar U, * Maciejewski W, * Link C, * Breit R, * Sigl H, * Robl H, * Preac-Mursic V. Dermatologische und Allergologische Abteilung, Staditischen Krankenhauses Munchen-Schwabing. Since the discovery that EM (erythema migrans), ACA (acrodermatitis chronica atrophicans) and BL (borrelial lymphocytoma) have an infectious etiology, these syndromes have been receiving particular attention. This report describes four patients whose dermatological symptoms did not at first indicate borreliosis. In all four cases serological antibody tests proved that they were caused by Borrelia burgdorferi. In two of these cases these findings were confirmed by bacterial cultures. The unusual skin symptoms, i.e. multiple disseminated erythema, erysipelas-like manifestations, swelling and discoloration of the eyelids and lichenoid papules, extend the known clinical spectrum of cutaneous borreliosis in Europe. PMID: 2759856 [PubMed - indexed for MEDLINE] ..............
|
|
|
Post by Niels on Nov 10, 2006 17:25:19 GMT -5
|
|
|
Post by grasshopper on Nov 10, 2006 18:48:51 GMT -5
You make good sense there Niels. To my knowlege Dr Harvey was first to make this connection with one of his patients.
|
|
|
Post by belikewater on Nov 11, 2006 12:32:25 GMT -5
Niels, thank you for this info. I had heard cutaneous Lyme was much more in evidence in Europe. Supposidly, a different species of Bb bacteria. Maybe it's partially because the cutaneous is overlooked here in the US. "Dumb as a Derm." ain't just a river in Egypt anymore.
|
|
|
Post by l46cheetah on Nov 11, 2006 14:03:02 GMT -5
MORE LIKE DERM AND DERMER............
|
|
|
Post by Orion*** on Nov 11, 2006 17:58:53 GMT -5
At first glance---I think the info. on this thread is very important---and most logical---Thanks neils
|
|
|
Post by godog on Nov 12, 2006 14:30:19 GMT -5
Haha, Derm and Dermer. Good one. Or maybe Derma*s applies too.
|
|
|
Post by Niels on Nov 14, 2006 16:21:45 GMT -5
In the IDSA "lyme guidelines" discussed here, note the following sections on dermatology issues (everything derm-related other than "erythema migrans" is below)
............ Acrodermatitis chronica atrophicans. Available data indicate that acrodermatitis chronica atrophicansmay be treated with a 21-day course of the same antibiotics (doxycycline [BII], amoxicillin [B-II], and cefuroxime axetil [B-III]) used to treat patients with erythema migrans (see above). A controlled study is warranted to compare oral with parenteral antibiotic therapy for the treatment of acrodermatitis chronica atrophicans. ............
LATE LYME DISEASE Primary Management Options Considered The panel considered various oral and parenteral antimicrobial regimens for treatment of the late manifestations of Lyme dis ease. Late manifestations include arthritis, encephalopathy, encephalomyelitis, and peripheral neuropathy. In view of the high frequency of travel between North America and Europe, acrodermatitis chronica atrophicans was addressed, despite its rarity in North America. Dermatologic manifestations that are even less common or less–well substantiated were not considered [201]
|
|
|
Post by Niels on Nov 14, 2006 16:37:40 GMT -5
It's interesting to look more closely at the specific research on derm manifestations of Lyme that are not considered by the IDSA in their guidelines because they're "less common or less-well substantiated" www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12637917&dopt=Abstract J Am Acad Dermatol. 2003 Mar;48(3):376-84. Interstitial granulomatous dermatitis with histiocytic pseudorosettes: a new histopathologic pattern in cutaneous borreliosis. Detection of Borrelia burgdorferi DNA sequences by a highly sensitive PCR-ELISA. * Moreno C, * Kutzner H, * Palmedo G, * Goerttler E, * Carrasco L, * Requena L. Department of Pathology, Fundacion Jimenez Diaz, Universidad Autonoma, Madrid, Spain. BACKGROUND: The cutaneous manifestations of Borrelia burgdorferi infection include an early phase of erythema chronicum migrans and a late stage of acrodermatitis chronica atrophicans lesions. OBJECTIVE: We describe 11 patients with peculiar cutaneous manifestations and distinctive histopathologic findings as the result of B burgdorferi infection. METHODS: Eleven patients with B burgdorferi detected by polymerase chain reaction or polymerase chain reaction enzyme-linked immunosorbent assay in their cutaneous lesions were included in this study. We analyzed clinical data and histopathologic findings in all patients. The inflammatory infiltrate was also immunohistochemically investigated. RESULTS: Most patients showed a peculiar clinical setting of morphea, and a few cases presented the characteristic appearance of erythema chronicum migrans instead of acrodermatitis chronica atrophicans, as would be expected in a late phase of B burgdorferi infection. The histopathologic findings were similar in all cases and consisted of an interstitial inflammatory infiltrate mostly composed of histiocytes dispersed among the collagen bundles of the dermis and focal areas of small pseudorosette formation, characterized by small histiocytes radially disposed around thick collagen bundles. In some cases there were also a few plasma cells intermingled with the histiocytes. CONCLUSION: Cutaneous lesions with clinical appearance similar to that of morphea and histopathologic features closely resembling those of the interstitial type of granuloma annular may be seen in intermediate-stage cutaneous lesions of B burgdorferi infection. These clinical and histopathologic findings represent a constellation of findings that have not been previously characterized as a cutaneous manifestation of B burgdorferi infection.
|
|
|
Post by belikewater on Nov 15, 2006 11:04:01 GMT -5
Niels, Thank you for your information. I do think Lyme Bb gets all over, even throughout the skin. However, I do not think at this point the specific Morgellons symptoms of fibers, cocoons, sharp spikules, etc., are specifically Lyme Bb.
I suspect my Lyme doctor feels this and gets frustraited with me that I am not jumping all over the Lyme treatments she offers. I have opted to take this slow as I from the begionning did not want to treat one or the other and let the remainders get worse.
My feeling is that the Lyme damages the immune system, lets yeasts overgrow in the skin leaving an open, attractive rout to other critters like mites or in some cases insects.
|
|
|
Post by Niels on Nov 20, 2006 17:19:40 GMT -5
Yay... it looks like someone is calling the IDSA on their bullshit!!
Business Wire Link
November 16, 2006 08:00 AM Eastern Time
Historic Move by CT Attorney General to Investigate IDSA Guidelines Process Gives Hope to Thousands of Lyme Disease Patients
Statement from Pat Smith, President, Lyme Disease Association
HARTFORD, Conn.--(BUSINESS WIRE)--The national non-profit Lyme Disease Association (LDA), representing more Lyme disease patients than any organization in the United States, applauds Connecticut State Attorney General Richard Blumenthal for beginning an investigation into the Infectious Diseases Society of America (IDSA) Lyme disease guidelines development process. In an unprecedented move, the Attorney Generals office filed a Civ il Investigative Demand (CID) to look into possible anti-trust violations by the IDSA in connection with exclusionary conduct and monopolization in the development of the Lyme guidelines.
Although unprecedented, the LDA feels this action is vitally necessary to protect the welfare of chronic Lyme patients nationwide whose treatments have been impacted by the stance taken by the IDSA. Their guidelines deny the existence of chronic infectious Lyme disease and list as not recommended most of the conventional medical treatments prescribed by physicians as well as alternative treatments often chosen by patients for any Lyme manifestation. Even some nutritional supplements should not be an option according to IDSA.
Clinical guidelines now drive the standard of care, and these IDSA guidelines have already been published on the CDC website. They are being used to deny treatment reimbursement and will have a continued chilling effect on the small numbers of treati ng physicians, since clinical discretion is not recommended in the guidelines.
The October 2006 guidelines do not acknowledge that a complex bacterium such as the Lyme disease spirochete could possibly survive in the body and the brain, evading the immune system and short-term courses of antibiotics, nor do they take into consideration any other professional diagnostic or treatment guidelines such as those published by the International Lyme and Associated Diseases Society (ILADS), which discuss chronic disease diagnostic and treatment modalities. The IDSA also refused to allow patient or chronic disease-treating physician input into the guidelines process through the LDA and ILADS, respectively, although both organizations requested to be a part of the process.
The national LDA and its affiliates Time for Lyme (CT) and the California Lyme Disease Association and ILADS, a professional medical organization, had appealed to the Attorney General on behalf of patie nts and treating physicians. We are encouraged by the issuance of the CID, and we hope that this will lead to actions that will guarantee patients the right to be treated and support physicians right to treat using clinical discretion.
|
|
|
Post by Niels on Nov 20, 2006 18:30:58 GMT -5
This is awesome news. It's about time the IDSA and the "mainstream" medical community got called on it's BS regarding Lyme treatment. This is important for all Morgies because right now, Lyme is the only diagnosis that might allow a morgellons sufferer to get the long-term medications needed to treat the disease. And the nematode component of Lyme is already understood by many Lyme literate doctors who know that tick-bites also routinely pass Nematode infections along with Lyme and other coinfections (ehlichia, babesia). I'd expect the next step is for some serious prosecution of LD's that prescribe medicines in disagreement with the "new prevailing practice" outlined by the IDSA's new guidelines. Thus the legal challenge to the IDSA is very timely. Especially because it runs ompletely against accepted practices for treatment in the lyme community; practices created by doctors seeing thousands of Lyme patients. A good example and a good paper to read in general) is www.canlyme.com/donta.htmlOne of Donta's conclusions is: > In patients with symptoms for more than a year, > 12-18 months may be needed for complete resolution of symptoms. > The rationale for a longer treatment course is based on extensive > observations (8,10), plus the analogy to the longer treatment courses > required for tuberculosis, leprosy, Q fever, and certain fungal diseases. That's a very different conclusion than what the IDSA came up with. And it's not like in the time when Donta wrote the abvove -- 2002 -- to today, any serious new proof has come in regarding the treatment of Lyme disease. The only studies that were conducted, had the FDA ensuring long-term treatment would fail -- because they artificially capped their clinical trials length of treatment at 3 months. Apparently excluded -- all the patients that have "LD"s and signed the waiver saying they "accept" experimental length-of-treatment outside of the accepted medical mainstream's one month. So in other words the people receiving successful treatment are being ignored, while the ones receiving unsuccessful treatment become the "guideline" ... ensuring unsuccessful treatment for all, courtesy of your friends at the FDA and CDC conducting "science" that is about as good as our intelligence on weapons of mass destruction in Iraq. The IDSA's new guidelines are one more way of preventing your treatment by the medical mainstream: The IDSA's guidelines, will be oversimplified by your idiot doctor to mean: (1) never prescribe antibiotics for more than 1 month to a morgie/lymey (2) if you've already had 1 month of antibiotics in the past (even if they were ineffective against Lyme or Morgellons) then you can't have Lyme disease anymore and therefore you can't have more antibiotics. (3) Any issues after that one month are "post lyme disease syndrome". Morgellons and other chronic lyme dermatoses (e.g. ACA) is just "post lyme disease syndrome" and like all the other lymies -- you're just supposed to live with it. Your idiot doctor will be telling you that lots of people live productive lives with a chronic illness and that I too must learn to suffer with this. (That's what my new insurance-co GP BS'd me with just last week.... new because my last insurance GP disagreed with my taking veterinary medicines and therefore refused to order the monthly blood/liver tests i needed to ensure I wasn't frying my organs). Furthermore, given the new guidelines, insurance companies will now have incontrovertible reason to not pay for antibiotic treatment past one month. (If you're lucky, perhaps they'll misdiagnose you with acne...for which you can get tetracycline for 6 months... which seems very effective against lyme -- I'm herxing like mad on Oxytetracycline "calf bolus" pillz right now -- i'm taking veterinary medicines precisely because i just got "boxed in" by my insurance company and insurance-covered doctors due to the IDSA guidelines... Someone enterprising should start mass-producing paste-on-zits so as to fool our dermatologists into thinking we have acne so we can get treated for Lyme with 6 months of tetracycline :-) Next time I go to the doc... i'll be sure to eat like 50 pounds of french fries and chocolate and sugar, do tons of speed and MDMA, and not shower for a few weeks... oh wait... I can just pay $44.00 to pbsanimalhealth.com and get a month worth of oxytetracycline for cows and avoid the idiot doctors, the IDSA's guidelines, the speed, the MDMA, the sugar and the grease, while also maintaining normal hygiene and not being subjected to psychological abuse by an evil doctor... What a plan!! That's my plan!
|
|
|
Post by Sidney on Nov 21, 2006 1:12:08 GMT -5
Niels, I've found many references to Ticks batting away Nematodes, but is there a specific citation or article of any kind that suggests a nematode infection could go hand in hand with Bb?
Thanks for all your research.
|
|
|
Post by hannah on Nov 21, 2006 19:53:30 GMT -5
Acrodermatitis chronica atrophicans - thanks for posting this information. Now I know what's wrong with my feet. Pity the dermatologists just thought I had DOP or is that Delusions of Acrodermatitis chronica atrophicans. Doesn't look as though they've even heard of it. I've printed out the article from www.emedicine.com/derm/topic4.htmThis is a really useful site as it has a facility for explaining the medical terminology. Yip, it's a whole new world now.
|
|
|
Post by Niels on Nov 22, 2006 15:03:33 GMT -5
and of course, there's absolutely no way that any good scientist or doctor might accidentally release one of their genetically modified borrelia infected animals into the wild -- or that "animal rights" activists freeing animals didn't accidentally free a new plague on the world once the modified bacteria got taken up by ticks in the wild.... ........... Title: Flagella-less borrelia Document Type and Number: United States Patent 5585102 Link to this Page: www.freepatentsonline.com/5585102.htmlAbstract: This invention relates to flagella-less strains of Borrelia to novel methods for use of the microorganisms as vaccines and in diagnostic assays. Although a preferred embodiment of the invention is directed to Borrelia burgdorferi, the present invention encompasses flagella-less strains of other microorganisms belonging to the genus Borrelia. Accordingly, with the aid of the disclosure, flagella-less mutants of other Borrelia species, e.g., B. coriacei, which causes epidemic bovine abortion, B. anserina, which causes avian spirochetosis, and B. recurrentis and other Borrelia species causative of relapsing fever, such as Borrelia hermsii, Borrelia turicatae, Borrelia duttoni, Borrelia persica, and Borrelia hispanica, can be prepared and used in accordance with the present invention and are within the scope of the invention. Therefore, a preferred embodiment comprises a composition of matter comprising a substantially pure preparation of a strain of a flagella-less microorganism belonging to the genus Borrelia.
|
|
|
Post by Niels on Nov 28, 2006 18:20:43 GMT -5
Niels, I've found many references to Ticks batting away Nematodes, but is there a specific citation or article of any kind that suggests a nematode infection could go hand in hand with Bb? on the first page of www.journals.uchicago.edu/CID/journal/issues/v25nS1/jy08_35/jy08_35.web.pdfthey mention experimental differences in dog-disease response between needle inoculation of dogs vs tick innoculation. The latter produced "persistent infection" and "polyarthritis". (hey, that's "my life as a dog" as well!) I vaguely recall this being based or postulated as being nematode-influenced, but I cannot seem to find that in the referenced paper: 13. Appel MJ, Allan S, Jacobson RH, et al. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis 1993;167: 651–64. which can be found here www.pubmedcentral.nih.gov/picrender.fcgi?artid=229521&blobtype=pdfI recall seeing a much better link in the past postulating possible nematode involvement but google is coming up short. I know that at the start of my Lyme treatment in July 2004 (in the earier days of morgellonhood) one of the first medicines I was prescribed, even before the ABX, was mebendazole for 1 week. The doctor says "ticks are the sewer of the parasite world" and listed off a host of possible coinfections including nematodes. I wish I had been less sceptical of this idea back then... would have saved me a world of hurt.
|
|